Lung Cancer最新文献

{"title":"Natural history models for lung Cancer: A scoping review","authors":"Renu Sara Nargund ,&nbsp;Sayaka Ishizawa ,&nbsp;Maryam Eghbalizarch ,&nbsp;Paul Yeh ,&nbsp;Seyyed Mostafa Mousavi Janbeh Saray ,&nbsp;Sara Nofal ,&nbsp;Yimin Geng ,&nbsp;Pianpian Cao ,&nbsp;Edwin J. Ostrin ,&nbsp;Rafael Meza ,&nbsp;Martin C. Tammemägi ,&nbsp;Robert J. Volk ,&nbsp;Maria A. Lopez-Olivo ,&nbsp;Iakovos Toumazis","doi":"10.1016/j.lungcan.2025.108495","DOIUrl":"10.1016/j.lungcan.2025.108495","url":null,"abstract":"<div><h3>Introduction</h3><div>Natural history models (NHMs) of lung cancer (LC) simulate the disease’s natural progression providing a baseline for assessing the impact of interventions. NHMs have been increasingly used to inform public health policies, highlighting their utility. The objective of this scoping review was to summarize existing LC NHMs, identify their limitations, and propose a framework for future NHM development.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, Web of Science, and IEEE Xplore from their inception to October 5, 2023, for peer-reviewed, full-length articles with an LC NHM. Model characteristics, their applications, data sources used, and limitations were extracted and narratively synthesized.</div></div><div><h3>Results</h3><div>From 238 publications, 69 publications were included in our review, corresponding to 22 original LC NHMs and 47 model applications. The majority of the models (n = 15, 68 %) used a microsimulation approach. NHM parameters were predominately informed by cancer registries, trial and institutional data, and literature. Model quality and performance were evaluated in 8 (36 %) models. Twenty (91 %) models included at least one carcinogenesis risk factor–primarily age, sex, and smoking history. Three (14 %) LC NHMs modeled progression in never-smokers; one (5 %) addressed recurrence. Non-tobacco smoking, nodule type, and biomarker expression were not considered in existing NHMs. Based on our findings, we proposed a framework for future LC NHM development which incorporates recurrence, nodule type differentiation, biomarker expression levels, biological factors, and non-smoking-related risk factors.</div></div><div><h3>Conclusion</h3><div>Regular updating and future research are warranted to address limitations in existing NHMs thereby ensuring relevance and accuracy of modeling approaches in the evolving LC landscape.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108495"},"PeriodicalIF":4.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Staging: Critical Insights into the Ninth TNM Edition for Lung Cancer","authors":"Olgun Keskin","doi":"10.1016/j.lungcan.2025.108502","DOIUrl":"10.1016/j.lungcan.2025.108502","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108502"},"PeriodicalIF":4.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning","authors":"T. Triwiyanto ,&nbsp;IPutu Alit Pawana ,&nbsp;Sari Luthfiyah","doi":"10.1016/j.lungcan.2025.108512","DOIUrl":"10.1016/j.lungcan.2025.108512","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108512"},"PeriodicalIF":4.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Letter to Editor-in-Chief” and “Redefining Resectability: Bridging Perspectives in Stage III NSCLC Management”","authors":"Ilias Houda ,&nbsp;Idris Bahce ,&nbsp;Jordi Remon ,&nbsp;Thierry Berghmans ,&nbsp;Corinne Faivre-Finn ,&nbsp;Anne-Marie C. Dingemans ,&nbsp;Benjamin Besse ,&nbsp;Lizza E.L. Hendriks","doi":"10.1016/j.lungcan.2025.108510","DOIUrl":"10.1016/j.lungcan.2025.108510","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108510"},"PeriodicalIF":4.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining resectability: Bridging perspectives in stage III NSCLC management","authors":"Luca Bertolaccini ,&nbsp;Monica Casiraghi ,&nbsp;Antonio Mazzella ,&nbsp;Lorenzo Spaggiari","doi":"10.1016/j.lungcan.2025.108509","DOIUrl":"10.1016/j.lungcan.2025.108509","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108509"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up)","authors":"Jelle E. Bousema ,&nbsp;Louisa N. Spaans ,&nbsp;Marcel G.W. Dijkgraaf ,&nbsp;Erik H.F.M. van der Heijden ,&nbsp;Ad F.T.M. Verhagen ,&nbsp;Jouke T. Annema ,&nbsp;Frank J.C. van den Broek","doi":"10.1016/j.lungcan.2025.108462","DOIUrl":"10.1016/j.lungcan.2025.108462","url":null,"abstract":"<div><div>Resectable non-small cell lung cancer (NSCLC) with increased risk of mediastinal nodal involvement requires invasive staging prior to surgical resection. The MEDIASTrial was a multicenter non-inferiority trial randomly assigning patients after negative endosonography to immediate lung tumor resection (n = 178) or to mediastinoscopy first (n = 182), only followed by tumor resection after negative mediastinoscopy. The omission of confirmatory mediastinoscopy after negative endosonography led to a clinically negligible and non-inferior increase in unforeseen N2.</div><div>We report the two-year overall and disease-free survival (OS and DFS) and the health-related quality-of-life (HRQoL) gathered with the QLQ-C30 and QLQ-LC13 questionnaires.</div><div>After randomization seven drop-outs were observed in both groups. Time to 80 % OS was 25 months in the immediate resection group versus 20 months in the mediastinoscopy group (adjusted HR 0.8, 95 % CI: 0.5–1.3). Time to 65 % DFS was 25 months in the immediate resection group versus 25 months in the mediastinoscopy group (adjusted HR 0.9, 95 % CI: 0.6–1.4). The HRQoL scores were comparable among the groups during the two-year follow-up.</div><div>The loss in diagnostic yield by omitting confirmatory mediastinoscopy after negative systematic endosonography has no impact on two-year OS, DFS and HRQoL in patients with resectable NSCLC and an indication for invasive mediastinal nodal staging.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108462"},"PeriodicalIF":4.5,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo drug testing of patient-derived lung organoids: The breakthrough of organotypic tissue slices for physiologically relevant imaging","authors":"V.A. Shestakova ,&nbsp;E.I. Smirnova ,&nbsp;D.S. Baranovskii ,&nbsp;I.D. Klabukov","doi":"10.1016/j.lungcan.2025.108503","DOIUrl":"10.1016/j.lungcan.2025.108503","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108503"},"PeriodicalIF":4.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma","authors":"Zhao An ,&nbsp;Ye Ning ,&nbsp;Jie Mei,&nbsp;Chenlu Yang,&nbsp;Xiaodong Yang","doi":"10.1016/j.lungcan.2025.108507","DOIUrl":"10.1016/j.lungcan.2025.108507","url":null,"abstract":"<div><h3>Objectives</h3><div>Adjuvant chemotherapy (ACT) for patients with stage IB lung adenocarcinoma (LUAD) is controversial, particularly in those with epidermal growth factor receptor (EGFR) mutations. This study aims to evaluate the efficacy of ACT in stage IB LUAD with Grade 3 and explore the prognostic impact of EGFR mutations status on chemotherapy effectiveness.</div></div><div><h3>Methods</h3><div>We identified 707 high-risk (Grade 3) stage IB LUAD patients who underwent complete resection between 2014 and 2018. The Kaplan-Meier curves was used to assess recurrence-free survival (RFS) and overall survival (OS). Prognostic factors were evaluated using the Cox proportional hazards model, and propensity score matching was applied to reduce bias from confounding variables.</div></div><div><h3>Results</h3><div>In the entire cohort, patients who received ACT showed significantly better 5-year RFS and OS compared to those who did not (P &lt; 0.001 for both). Among 247 patients without EGFR mutations, 125 (50.6 %) received ACT and 122 (49.4 %) did not. In the propensity score-matched cohort of 84 pairs, those treated with ACT had significantly better 5-year RFS and OS (P &lt; 0.01 for both). Among 460 patients with EGFR mutations, 237 (51.5 %) received ACT and 223 (48.5 %) did not. In the matched cohort of 184 pairs, ACT recipients had significantly better prognoses. Multivariable analysis confirmed ACT was an independent prognostic factor, while EGFR mutation status was not.</div></div><div><h3>Conclusions</h3><div>ACT significantly improves the prognosis of patients with Grade 3 stage IB LUAD, irrespective of EGFR mutation status. These findings support the clinical adoption of ACT for this patient subgroup.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108507"},"PeriodicalIF":4.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors","authors":"Kazuya Takamochi ,&nbsp;Kenji Suzuki ,&nbsp;Morihito Okada ,&nbsp;Seiji Niho ,&nbsp;Satoshi Ishikura ,&nbsp;Shunsuke Oyamada ,&nbsp;Takuhiro Yamaguchi ,&nbsp;Hirotoshi Horio ,&nbsp;Norihiko Ikeda ,&nbsp;Fumihiro Tanaka ,&nbsp;Satoshi Shiono ,&nbsp;Tomohiro Haruki ,&nbsp;Ichiro Yoshino ,&nbsp;Hiroyuki Ito ,&nbsp;Hidetaka Uramoto ,&nbsp;Norihito Okumura ,&nbsp;Hisashi Iwata ,&nbsp;Hisashi Saji ,&nbsp;Toshiya Fujiwara ,&nbsp;Kazuhito Funai ,&nbsp;Masahiro Tsuboi","doi":"10.1016/j.lungcan.2025.108506","DOIUrl":"10.1016/j.lungcan.2025.108506","url":null,"abstract":"<div><h3>Purpose</h3><div>This multicenter single-arm confirmatory trial (CRES³T) investigated the efficacy and safety of S-1 + cisplatin and concurrent radical-dose radiotherapy followed by surgery in patients with a superior sulcus tumor.</div></div><div><h3>Methods</h3><div>Patients received induction therapy comprising three cycles of S-1 + cisplatin with concurrent radiotherapy (66 Gy in 33 fractions) followed by surgery. S-1 was administered orally at 40 mg/m² twice/day on days 1–14, with an intravenous infusion of cisplatin (60 mg/m²) on day 1. The primary endpoint was the 3-year overall survival rate; key secondary endpoints included progression-free survival rate, objective response rate, pathological complete response rate, and toxicity.</div></div><div><h3>Results</h3><div>Sixty-one patients with a superior sulcus non-small cell lung cancer received induction therapy. Radiological tumor invasion sites were the chest wall (n = 57), subclavian artery (n = 18), and subclavian vein (n = 10). Forty-nine patients underwent a lobectomy and combined resection of the involved structures. The objective and pathological complete response rates were 42 % (95 % confidence interval: 29–54 %) and 33 % (95 % confidence interval: 20–46 %), respectively. The 3-year overall survival and progression-free survival rates were 73.2 % (95 % confidence interval: 60.1–82.7 %) and 53.3 % (95 % confidence interval: 40.0–65.0 %), respectively. The patterns of first tumor relapse were locoregional only in one, distant metastasis only in 18, and both in four patients. Two pneumonia cases during induction therapy and one cardiac-arrest case on postoperative day 3 resulted in death.</div></div><div><h3>Conclusions</h3><div>Induction therapy using S-1 + cisplatin and concurrent radical-dose radiotherapy followed by surgery maximized local control and improved overall survival without impairing safety, potentially representing a new standard treatment.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108506"},"PeriodicalIF":4.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention","authors":"Kari Hemminki ,&nbsp;Frantisek Zitricky ,&nbsp;Kristina Sundquist ,&nbsp;Jan Sundquist ,&nbsp;Asta Försti ,&nbsp;Akseli Hemminki","doi":"10.1016/j.lungcan.2025.108500","DOIUrl":"10.1016/j.lungcan.2025.108500","url":null,"abstract":"<div><h3>Introduction</h3><div>Familial risk of lung cancer (LC) is at the level of many common cancers (ca 2.0) but as cigarette smoking is the main cause of LC, it has remained undefined to what extent smoking contributes to the familial risk. We take advantage of the natural experiment of divorce. In Sweden, it has been customary that children stay with their mother after divorce. We thus hypothesize that only maternal half-siblings share the childhood environment to the same extent than full siblings.</div></div><div><h3>Methods</h3><div>We used Swedish nation-wide data on family structures and cancers up to year 2021 to determined LC risk (standardized incidence ratio, SIR with 95% confidence intervals) in maternal and paternal half-siblings and in full siblings.</div></div><div><h3>Results</h3><div>Familial risk for LC in maternal half-siblings was 2.21 (1.76–2.77) which was not different from that of full siblings 2.23 (2.22–2.44). For paternal half-siblings the risk was 1.56 (1.21–2.01). For adenocarcinoma the risks were for full siblings 2.36 (2.23–2.51), for maternal half-siblings 2.55 (1.93–3.35) and for paternal half-siblings 1.33 (0.94–1.87).</div></div><div><h3>Conclusions</h3><div>The results showed that familial risk for LC was equal in full siblings and in maternal half-siblings; the risks for paternal half-siblings were lower and for adenocarcinoma significantly lower than those for full siblings. The results suggest that smoking is a major contributor to familial risk of LC in this setting. Smoking starts at an early age and anti-smoking campaigns should target childhood environment for prevention of smoking initiation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108500"},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}